Selective allosteric inhibition of MMP9 is efficacious in preclinical models of ulcerative colitis and colorectal cancer

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Marshall, Derek C ^a   Lyman, Susan K ^a   McCauley, Scott ^a   Kovalenko, Maria ^a   Spangler, Rhyannon ^a   Liu, Chian ^a   Lee, Michael ^a   O'Sullivan, Christopher ^a   Barry Hamilton, Vivian ^a   Ghermazien, Haben ^a   Mikels Vigdal, Amanda ^a   Garcia, Carlos A ^a   Jorgensen, Brett ^a   Velayo, Arleene C ^a   Wang, Ruth ^a   Adamkewicz, Joanne I ^a   Smith, Victoria ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AB 0041; AB 0046; ANTIBODY; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; GELATINASE B; GS 5745; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; DEXTRAN SULFATE; MATRIX METALLOPROTEINASE INHIBITOR; RECOMBINANT PROTEIN;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; MALE; METASTASIS INHIBITION; MOUSE; MUSCULOSKELETAL DISEASE; NONHUMAN; PROTEIN DEGRADATION; RAT; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; DISEASE MODEL; DRUG SCREENING; ENZYMOLOGY; EPITOPE MAPPING; GENE EXPRESSION REGULATION; GENETICS; HYBRIDOMA; IMMUNOLOGY; ISOLATION AND PURIFICATION; LEWIS RAT; METABOLISM; NUDE MOUSE; PATHOLOGY; PRECLINICAL STUDY;

RATTUS;

ALLOSTERIC REGULATION; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EPITOPE MAPPING; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYBRIDOMAS; MALE; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; MICE; MICE, NUDE; RATS; RATS, INBRED LEW; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930657806     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127063     Document Type: Article

References (116)

1. Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nature reviews Drug discovery. 2007; 6(6):480-98. PMID: 17541420
2. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010; 141(1):52-67. doi: 10.1016/j.cell.2010.03.015 PMID: 20371345
3. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nature reviews Molecular cell biology. 2007; 8(3):221-33. PMID: 17318226
4. Rodriguez D, Morrison CJ, Overall CM. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochimica et biophysica acta. 2010; 1803(1):39-54. doi: 10.1016/j.bbamcr.2009.09.015 PMID: 19800373
5. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27(31):5287-97.
6. Vandooren J, Van den Steen PE, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Critical reviews in biochemistry and molecular biology. 2013; 48(3):222-72. doi: 10.3109/10409238.2013.770819 PMID: 23547785
7. Ram M, Sherer Y, Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. Journal of clinical immunology. 2006; 26(4):299-307. PMID: 16652230
8. Ahrens D, Koch AE, Pope RM, Stein-Picarella M, Niedbala MJ. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis and rheumatism. 1996; 39 (9):1576-87. PMID: 8814070
9. Chang YH, Lin IL, Tsay GJ, Yang SC, Yang TP, Ho KT, et al. Elevated circulatory MMP-2 and MMP-9 levels and activities in patients with rheumatoid arthritis and systemic lupus erythematosus. Clinical biochemistry. 2008; 41(12):955-9. doi: 10.1016/j.clinbiochem.2008.04.012 PMID: 18471998
10. Gao Q, Meijer MJ, Kubben FJ, Sier CF, Kruidenier L, van Duijn W, et al. Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2005; 37(8):584-92.
11. Lakatos G, Sipos F, Miheller P, Hritz I, Varga MZ, Juhasz M, et al. The behavior of matrix metalloproteinase-9 in lymphocytic colitis, collagenous colitis and ulcerative colitis. Pathology oncology research: POR. 2012; 18(1):85-91. doi: 10.1007/s12253-011-9420-9 PMID: 21678108
12. Pedersen G, Saermark T, Kirkegaard T, Brynskov J. Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epithelium. Clinical and experimental immunology. 2009; 155(2):257-65. doi: 10.1111/j.1365-2249.2008.03836.x PMID: 19137636
13. Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012; 380(9853):1606-19. doi: 10.1016/S0140-6736(12)60150-0 PMID: 22914296
14. th ed. New York2003. p. 255-76.
15. Thorsteinsdottir S, Gudjonsson T, Nielsen OH, Vainer B, Seidelin JB. Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis. Nature reviews Gastroenterology & hepatology. 2011; 8 (7):395-404.
16. Williams JW, Shepherd NA. Pathology of chronic inflammatory bowel disease. Surgery. 2005; 23(10):346-9.
17. Peterson JT. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovascular research. 2006; 69(3):677-87. PMID: 16413004
18. Ben David D, Reznick AZ, Srouji S, Livne E. Exposure to pro-inflammatory cytokines upregulates MMP-9 synthesis by mesenchymal stem cells-derived osteoprogenitors. Histochemistry and cell biology. 2008; 129(5):589-97. doi: 10.1007/s00418-008-0391-1 PMID: 18274772
19. Ben-David D, Livne E, Reznick AZ. The involvement of oxidants and NF-kappaB in cytokine-induced MMP-9 synthesis by bone marrow-derived osteoprogenitor cells. Inflammation research: official journal of the European Histamine Research Society [et al]. 2012; 61(7):673-88. doi: 10.1007/s00011-012-0461-7 PMID: 22410640
20. Drygiannakis I, Valatas V, Sfakianaki O, Bourikas L, Manousou P, Kambas K, et al. Proinflammatory cytokines induce crosstalk between colonic epithelial cells and subepithelial myofibroblasts: implication in intestinal fibrosis. Journal of Crohn's & colitis. 2013; 7(4):286-300.
21. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature. 1994; 370(6490):555-7. PMID: 8052310
22. Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino acids. 2011; 41(2):271-90. doi: 10.1007/s00726-010-0689-x PMID: 20640864
23. Opdenakker G, Van den Steen PE, Van Damme J. Gelatinase B: a tuner and amplifier of immune functions. Trends in immunology. 2001; 22(10):571-9. PMID: 11574282
24. Schonbeck U, Mach F, Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol. 1998; 161 (7):3340-6. PMID: 9759850
25. Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood. 2000; 96(8):2673-81. PMID: 11023497
26. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes & development. 2000; 14(2):163-76.
27. Grossmann J. Molecular mechanisms of "detachment-induced apoptosis - Anoikis". Apoptosis: an international journal on programmed cell death. 2002; 7(3):247-60. PMID: 11997669
28. Delclaux C, Delacourt C, D'Ortho MP, Boyer V, Lafuma C, Harf A. Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane. American journal of respiratory cell and molecular biology. 1996; 14(3):288-95. PMID: 8845180
29. D'Haese A, Wuyts A, Dillen C, Dubois B, Billiau A, Heremans H, et al. In vivo neutrophil recruitment by granulocyte chemotactic protein-2 is assisted by gelatinase B/MMP-9 in the mouse. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research. 2000; 20(7):667-74.
30. Goetzl EJ, Banda MJ, Leppert D. Matrix metalloproteinases in immunity. J Immunol. 1996; 156(1):1-4. PMID: 8598448
31. Jawad N, Direkze N, Leedham SJ. Inflammatory bowel disease and colon cancer. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer. 2011; 185:99-115. doi: 10.1007/978-3-642-03503-6-6 PMID: 21822822
32. Neumann H, Vieth M, Langner C, Neurath MF, Mudter J. Cancer risk in IBD: how to diagnose and how to manage DALM and ALM. World journal of gastroenterology: WJG. 2011; 17(27):3184-91. doi: 10.3748/wjg.v17.i27.3184 PMID: 21912466
33. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology. 2011; 140(6):1807-16. doi: 10.1053/j.gastro.2011.01.057 PMID: 21530747
34. Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjanen S, Syrjanen K, et al. MMP-9 (gelatinase B) expression is associated with disease-free survival and disease-specific survival in colorectal cancer patients. Cancer investigation. 2010; 28(1):38-43. doi: 10.3109/07357900802672761 PMID: 20001295
35. Buhmeida A, Bendardaf R, Hilska M, Collan Y, Laato M, Syrjanen S, et al. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in stage II colorectal carcinoma. Journal of gastrointestinal cancer. 2009; 40(3-4):91-7. doi: 10.1007/s12029-009-9104-9 PMID: 19921473
36. Ogata Y, Matono K, Sasatomi T, Ishibashi N, Ohkita A, Mizobe T, et al. The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. Cancer chemotherapy and pharmacology. 2006; 57(5):577-83. PMID: 16133529
37. Svagzdys S, Lesauskaite V, Pangonyte D, Saladzinskas Z, Tamelis A, Pavalkis D. Matrix metalloproteinase-9 is a prognostic marker to predict survival of patients who underwent surgery due to rectal carcinoma. The Tohoku journal of experimental medicine. 2011; 223(1):67-73. PMID: 21212604
38. Chu D, Zhao Z, Zhou Y, Li Y, Li J, Zheng J, et al. Matrix metalloproteinase-9 is associated with relapse and prognosis of patients with colorectal cancer. Annals of surgical oncology. 2012; 19(1):318-25. doi: 10.1245/s10434-011-1686-3 PMID: 21455597
39. Vihinen P, Ala-aho R, Kahari VM. Matrix metalloproteinases as therapeutic targets in cancer. Current cancer drug targets. 2005; 5(3):203-20. PMID: 15892620
40. Al-Batran SE, Pauligk C, Wirtz R, Werner D, Steinmetz K, Homann N, et al. The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2012; 23(7):1699-705.
41. Iniesta P, Moran A, De Juan C, Gomez A, Hernando F, Garcia-Aranda C, et al. Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer. Oncology reports. 2007; 17(1):217-23. PMID: 17143501
42. Kuniyasu H, Ellis LM, Evans DB, Abbruzzese JL, Fenoglio CJ, Bucana CD, et al. Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 1999; 5(1):25-33. PMID: 9918199
43. Lukaszewicz-Zajac M, Mroczko B, Szmitkowski M. Gastric cancer - The role of matrix metalloproteinases in tumor progression. Clinica chimica acta; international journal of clinical chemistry. 2011; 412 (19-20):1725-30.
44. Maatta M, Soini Y, Liakka A, Autio-Harmainen H. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clinical cancer research: an official journal of the American Association for Cancer Research. 2000; 6(7):2726-34. PMID: 10914717
45. Shao W, Wang W, Xiong XG, Cao C, Yan TD, Chen G, et al. Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage IA non-small cell lung cancer. Journal of surgical oncology. 2011; 104 (7):841-6. doi: 10.1002/jso.22001 PMID: 21721010
46. Simi L, Andreani M, Davini F, Janni A, Pazzagli M, Serio M, et al. Simultaneous measurement of MMP9 and TIMP1 mRNA in human non small cell lung cancers by multiplex real time RT-PCR. Lung Cancer. 2004; 45(2):171-9. PMID: 15246188
47. Yang Q, Ye ZY, Zhang JX, Tao HQ, Li SG, Zhao ZS. Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis. Anat Rec (Hoboken). 2010; 293(12):2012-9. doi: 10.1002/ar.21071 PMID: 21089052
48. Allen M, Louise Jones J. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. The Journal of pathology. 2011; 223(2):162-76. doi: 10.1002/path.2803 PMID: 21125673
49. Baay M, Brouwer A, Pauwels P, Peeters M, Lardon F. Tumor Cells and Tumor-Associated Macrophages: Secreted Proteins as Potential Targets for Therapy. Clin Dev Immunol. 2011.
50. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006; 124(2):263-6. PMID: 16439202
51. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer cell. 2012; 21(3):309-22. doi: 10.1016/j.ccr.2012.02.022 PMID: 22439926
52. Shih J-Y, Yuan A, Chen JJ-W, Yang PC. Tumor-associated macrophage: Its role in cancer invasion and metastasis. J Canc Molec. 2006; 2(3):101-6.
53. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer metastasis reviews. 2006; 25(1):9-34. PMID: 16680569
54. Beliveau A, Mott JD, Lo A, Chen EI, Koller AA, Yaswen P, et al. Raf-induced MMP9 disrupts tissue architecture of human breast cells in three-dimensional culture and is necessary for tumor growth in vivo. Genes & development. 2010; 24(24):2800-11.
55. Genersch E, Hayess K, Neuenfeld Y, Haller H. Sustained ERK phosphorylation is necessary but not sufficient for MMP-9 regulation in endothelial cells: involvement of Ras-dependent and-independent pathways. Journal of cell science. 2000; 113 Pt 23:4319-30. PMID: 11069776
56. Holvoet S, Vincent C, Schmitt D, Serres M. The inhibition of MAPK pathway is correlated with down-regulation of MMP-9 secretion induced by TNF-alpha in human keratinocytes. Experimental cell research. 2003; 290(1):108-19. PMID: 14516792
57. Lakka SS, Jasti SL, Gondi C, Boyd D, Chandrasekar N, Dinh DH, et al. Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro. Oncogene. 2002; 21(36):5601-8. PMID: 12165859
58. Sela-Passwell N, Kikkeri R, Dym O, Rozenberg H, Margalit R, Arad-Yellin R, et al. Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential. Nature medicine. 2012; 18(1):143-7. doi: 10.1038/nm.2582 PMID: 22198278
59. Crampton SP, Wu B, Park EJ, Kim JH, Solomon C, Waterman ML, et al. Integration of the beta-catenin-dependent Wnt pathway with integrin signaling through the adaptor molecule Grb2. PloS one. 2009; 4(11):e7841. doi: 10.1371/journal.pone.0007841 PMID: 19924227
60. Fukuyama R, Ng KP, Cicek M, Kelleher C, Niculaita R, Casey G, et al. Role of IKK and oscillatory NFkappaB kinetics in MMP-9 gene expression and chemoresistance to 5-fluorouracil in RKO colorectal cancer cells. Molecular carcinogenesis. 2007; 46(5):402-13. PMID: 17186550
61. Li J, Lau GK, Chen L, Dong SS, Lan HY, Huang XR, et al. Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression. PloS one. 2011; 6(7):e21816. doi: 10.1371/journal.pone.0021816 PMID: 21760911
62. Vaid M, Prasad R, Sun Q, Katiyar SK. Silymarin targets beta-catenin signaling in blocking migration/invasion of human melanoma cells. PloS one. 2011; 6(7):e23000. doi: 10.1371/journal.pone.0023000 PMID: 21829575
63. Yoon SO, Shin S, Lee HJ, Chun HK, Chung AS. Isoginkgetin inhibits tumor cell invasion by regulating phosphatidylinositol 3-kinase/Akt-dependent matrix metalloproteinase-9 expression. Molecular cancer therapeutics. 2006; 5(11):2666-75. PMID: 17121913
64. Ardi VC, Van den Steen PE, Opdenakker G, Schweighofer B, Deryugina EI, Quigley JP. Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway. The Journal of biological chemistry. 2009; 284(38):25854-66. doi: 10.1074/jbc.M109.033472 PMID: 19608737
65. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature cell biology. 2000; 2(10):737-44. PMID: 11025665
66. Deryugina EI, Quigley JP. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochimica et biophysica acta. 2010; 1803(1):103-20. doi: 10.1016/j.bbamcr.2009.09.017 PMID: 19800930
67. Perng DW, Chang KT, Su KC, Wu YC, Chen CS, Hsu WH, et al. Matrix metalloprotease-9 induces transforming growth factor-beta(1) production in airway epithelium via activation of epidermal growth factor receptors. Life sciences. 2011; 89(5-6):204-12.
68. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochimica et biophysica acta. 2012; 1825 (1):29-36. doi: 10.1016/j.bbcan.2011.10.001 PMID: 22020293
69. Woo J. Mesencyhme-epithelial interactions in gastrointestinal development and tumorigenesis [PhD]: Harvard University; 2011.
70. Ahn GO, Brown JM. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer cell. 2008; 13(3):193-205. doi: 10.1016/j.ccr.2007.11.032 PMID: 18328424
71. Ardi VC, Kupriyanova TA, Deryugina EI, Quigley JP. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(51):20262-7. PMID: 18077379
72. Coffelt SB, Hughes R, Lewis CE. Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochimica et biophysica acta. 2009; 1796(1):11-8. doi: 10.1016/j.bbcan.2009.02.004 PMID: 19269310
73. Nakamura T, Kuwai T, Kim JS, Fan D, Kim SJ, Fidler IJ. Stromal metalloproteinase-9 is essential to angiogenesis and progressive growth of orthotopic human pancreatic cancer in parabiont nude mice. Neoplasia. 2007; 9(11):979-86. PMID: 18030366
74. Castaneda FE, Walia B, Vijay-Kumar M, Patel NR, Roser S, Kolachala VL, et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology. 2005; 129(6):1991-2008. PMID: 16344067
75. Fanjul-Fernandez M, Folgueras AR, Cabrera S, Lopez-Otin C. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochimica et biophysica acta. 2010; 1803 (1):3-19. doi: 10.1016/j.bbamcr.2009.07.004 PMID: 19631700
76. Garg P, Vijay-Kumar M, Wang L, Gewirtz AT, Merlin D, Sitaraman SV. Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis. American journal of physiology Gastrointestinal and liver physiology. 2009; 296(2):G175-84. doi: 10.1152/ajpgi.90454.2008 PMID: 19171847
77. Itoh T, Matsuda H, Tanioka M, Kuwabara K, Itohara S, Suzuki R. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J Immunol. 2002; 169(5):2643-7. PMID: 12193736
78. Kruger A. Functional genetic mouse models: promising tools for investigation of the proteolytic internet. Biological chemistry. 2009; 390(2):91-7. doi: 10.1515/BC.2009.015 PMID: 19040350
79. Naito Y, Yoshikawa T. Role of matrix metalloproteinases in inflammatory bowel disease. Molecular aspects of medicine. 2005; 26(4-5):379-90. PMID: 16099026
80. Santana A, Medina C, Paz-Cabrera MC, Diaz-Gonzalez F, Farre E, Salas A, et al. Attenuation of dextran sodium sulphate induced colitis in matrix metalloproteinase-9 deficient mice. World journal of gastroenterology: WJG. 2006; 12(40):6464-72. PMID: 17072979
81. Martin MD, Carter KJ, Jean-Philippe SR, Chang M, Mobashery S, Thiolloy S, et al. Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer research. 2008; 68(15):6251-9. doi: 10.1158/0008-5472.CAN-08-0537 PMID: 18676849
82. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002; 295(5564):2387-92. PMID: 11923519
83. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. Journal of the National Cancer Institute. 2001; 93(3):178-93. PMID: 11158186
84. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nature reviews Cancer. 2002; 2(9):657-72. PMID: 12209155
85. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular research. 2006; 69(3):562-73. PMID: 16405877
86. Knight CG, Willenbrock F, Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS letters. 1992; 296(3):263-6. PMID: 1537400
87. Ogata Y, Itoh Y, Nagase H. Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. The Journal of biological chemistry. 1995; 270(31):18506-11. PMID: 7629179
88. Renkiewicz R, Qiu L, Lesch C, Sun X, Devalaraja R, Cody T, et al. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis and rheumatism. 2003; 48(6):1742-9. PMID: 12794843
89. Lyng G, Stevens C, Watkins B, Fey E, Sonis S. Mouse video endoscopy. A novel method in the preclinical development of Inflammatory Bowel Disease therapies. Inflammatory bowel diseases. 2009; 15(12):S48-S9.
90. Elkins PA, Ho YS, Smith WW, Janson CA, D'Alessio KJ, McQueney MS, et al. Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix metalloproteinase. Acta crystallographica Section D, Biological crystallography. 2002; 58(Pt 7):1182-92. PMID: 12077439
91. Koboziev I, Karlsson F, Zhang S, Grisham MB. Pharmacological intervention studies using mouse models of the inflammatory bowel diseases: translating preclinical data into new drug therapies. Inflammatory bowel diseases. 2011; 17(5):1229-45. doi: 10.1002/ibd.21557 PMID: 21312318
92. Okayasu I, Yamada M, Mikami T, Yoshida T, Kanno J, Ohkusa T. Dysplasia and carcinoma development in a repeated dextran sulfate sodium-induced colitis model. Journal of gastroenterology and hepatology. 2002; 17(10):1078-83. PMID: 12201867
93. Solomon L, Mansor S, Mallon P, Donnelly E, Hoper M, Loughrey M, et al. The dextran sulphate sodium (DSS) model of colitis: an overview. Comp Clin Pathol. 2010; 19:235-9.
94. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 1993; 151(3):1548-61. PMID: 8393046
95. Gooz M. ADAM-17: the enzyme that does it all. Critical reviews in biochemistry and molecular biology. 2010; 45(2):146-69. doi: 10.3109/10409231003628015 PMID: 20184396
96. Acuff HB, Carter KJ, Fingleton B, Gorden DL, Matrisian LM. Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. Cancer research. 2006; 66(1):259-66. PMID: 16397239
97. Hawinkels LJ, Zuidwijk K, Verspaget HW, de Jonge-Muller ES, van Duijn W, Ferreira V, et al. VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. Eur J Cancer. 2008; 44(13):1904-13. doi: 10.1016/j.ejca.2008.06.031 PMID: 18691882
98. Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nature biotechnology. 2009; 27(8):767-71. doi: 10.1038/nbt.1553 PMID: 19620983
99. Salfeld JG. Isotype selection in antibody engineering. Nature biotechnology. 2007; 25(12):1369-72. PMID: 18066027
100. Devy L, Dransfield DT. New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies. Biochemistry research international. 2011; 2011:191670. doi: 10.1155/2011/191670 PMID: 21152183
101. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. The FEBS journal. 2011; 278(1):16-27. doi: 10.1111/j.1742-4658.2010.07919.x PMID: 21087457
102. Wang X, Li KF, Adams E, Van Schepdael A. Matrix metalloproteinase inhibitors: a review on bioanalytical methods, pharmacokinetics and metabolism. Current drug metabolism. 2011; 12(4):395-410. PMID: 21395524
103. nd ed: John Wiley & Sons, Inc.; 2013. PMID: 16350889
104. Paemen L, Martens E, Masure S, Opdenakker G. Monoclonal antibodies specific for natural human neutrophil gelatinase B used for affinity purification, quantitation by two-site ELISA and inhibition of enzymatic activity. European journal of biochemistry / FEBS. 1995; 234(3):759-65. PMID: 8575432
105. Bezzio C, Furfaro F, de Franchis R, Maconi G, Asthana AK, Ardizzone S. Ulcerative colitis: current pharmacotherapy and future directions. Expert opinion on pharmacotherapy. 2014:1-12. doi: 10.1517/14656566.2015.980724 PMID: 25387541
106. Guo Y, Lu N, Bai A. Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update. BioMed research international. 2013; 2013:581631. doi: 10.1155/2013/581631 PMID: 23484133
107. Silva LC, Ortigosa LC, Benard G. Anti-TNF-alpha agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy. 2010; 2(6):817-33. doi: 10.2217/imt.10.67 PMID: 21091114
108. Ali T, Kaitha S, Mahmood S, Ftesi A, Stone J, Bronze MS. Clinical use of anti-TNF therapy and increased risk of infections. Drug, healthcare and patient safety. 2013; 5:79-99. doi: 10.2147/DHPS.S28801 PMID: 23569399
109. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. The New England journal of medicine. 2005; 353(23):2462-76. PMID: 16339095
110. Opdenakker G, Van den Steen PE, Dubois B, Nelissen I, Van Coillie E, Masure S, et al. Gelatinase B functions as regulator and effector in leukocyte biology. Journal of leukocyte biology. 2001; 69(6):851-9. PMID: 11404367
111. Annahazi A, Molnar T, Farkas K, Rosztoczy A, Izbeki F, Gecse K, et al. Fecal MMP-9: a new noninvasive differential diagnostic and activity marker in ulcerative colitis. Inflammatory bowel diseases. 2013; 19(2):316-20. doi: 10.1002/ibd.22996 PMID: 22550024
112. Alvarez OA, Carmichael DF, DeClerck YA. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. Journal of the National Cancer Institute. 1990; 82(7):589-95. PMID: 2156082
113. Stetler-Stevenson WG. Type IV collagenases in tumor invasion and metastasis. Cancer metastasis reviews. 1990; 9(4):289-303. PMID: 1965794
114. Gerg M, Kopitz C, Schaten S, Tschukes A, Kahlert C, Stangl M, et al. Distinct functionality of tumor cell-derived gelatinases during formation of liver metastases. Molecular cancer research: MCR. 2008; 6(3):341-51. doi: 10.1158/1541-7786.MCR-07-2032 PMID: 18337444
115. Chetty C, Lakka SS, Bhoopathi P, Gondi CS, Veeravalli KK, Fassett D, et al. Urokinase plasminogen activator receptor and/or matrix metalloproteinase-9 inhibition induces apoptosis signaling through lipid rafts in glioblastoma xenograft cells. Molecular cancer therapeutics. 2010; 9(9):2605-17. doi: 10.1158/1535-7163.MCT-10-0245 PMID: 20716639
116. Nalla AK, Gorantla B, Gondi CS, Lakka SS, Rao JS. Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells. Cancer gene therapy. 2010; 17(9):599-613. doi: 10.1038/cgt.2010.16 PMID: 20448670